Preferential killing of cancer cells with mitochondrial dysfunction by natural compounds |
| |
| Authors: | Gang Chen Feng Wang Dunyaporn Trachootham Peng Huang |
| |
| Institution: | 1. David Geffen School of Medicine, UCLA, Los Angeles, CA, USA;2. Mary Crowley Cancer Research Centers, Dallas, TX, USA;1. Department of Clinical Chemistry, Endocrine Laboratory, VU University Medical Center, Amsterdam, The Netherlands;2. Centers for Disease Control and Prevention (CDC), Division of Laboratory Sciences, Atlanta, GA, United States;3. Department of Laboratory Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands;4. Department of Clinical Chemistry, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands;5. Department of Laboratory Medicine, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands;6. Department of Clinical Chemistry and Laboratory Medicine, Medical Spectrum Twente, Medlon BV, The Netherlands;1. Department of Toxicology and Pharmacology, Faculty of Pharmacy, and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran;2. Department of Toxicology and Pharmacology, Faculty of Pharmacy, and Pharmaceutical Sciences Research Center, Kerman University of Medical Sciences, Kerman, Iran |
| |
| Abstract: | Mitochondria play essential roles in cellular metabolism, redox homeostasis, and regulation of cell death. Emerging evidences suggest that cancer cells exhibit various degrees of mitochondrial dysfunctions and metabolic alterations, which may serve as a basis to develop therapeutic strategies to preferentially kill the malignant cells. Mitochondria as a therapeutic target for cancer treatment is gaining much attention in the recent years, and agents that impact mitochondria with anticancer activity have been identified and tested in vitro and in vivo using various experimental systems. Anticancer agents that directly target mitochondria or indirectly affect mitochondrial functions are collectively classified as mitocans. This review article focuses on several natural compounds that preferentially kill cancer cells with mitochondrial dysfunction, and discusses the possible underlying mechanisms and their therapeutic implications in cancer treatment. Mitocans that have been comprehensively reviewed recently are not included in this article. Important issues such as therapeutic selectivity and the relevant biochemical basis are discussed in the context of future perspectives. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
